Although nixed in 2017, remnants of the GW Pharmaceuticals plc and Otsuka Pharmaceuticals Co. Limited partnership are still publishing to the USPTO database. In December of 2017, GW Pharmaceuticals regained full rights to develop and commercialize Sativex® in the U.S., which since 2007 had been licensed to Otsuka Pharmaceuticals. Otsuka Pharmaceuticals assisted immensely with financials for the R&D of Sativex in the U.S. and will still receive contingent milestone payments if the drug becomes FDA-approved or reaches sales marks in the U.S. To put Otsuka’s efforts into context, GW Pharmaceuticals only made $8.7 million from sales of Sativex in 2017 but required $150 million for R&D during the 2017 fiscal year, which Otsuka aided with.
Sativex is an oral spray containing extracts from cannabis of the cannabinoids THC and CBD. GW Pharmaceuticals and Otsuka Pharmaceuticals were just jointly granted U.S. Patent No. 10,799,467 entitled, “Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy.” The two companies are jointly assigned eighteen (18) published patent applications with nine (9) having matured into issued patents, thus far. Their patents and patent applications are related to neurological, cancer, and pain medications containing cannabinoids.
Explore the dense portfolio of GW Pharmaceuticals and Otsuka Pharmaceuticals through the Magic Number® Cannabis Patent Forecast®. Market and patent data are combined to give companies and investors the competitive edge they need. Start your free trial today!
-LOgDn.jpg)